ASX - By Stock
|
LOT |
Re:
LOT Chart
|
|
Dungiven
|
315 |
147K |
0 |
23/08/24 |
23/08/24 |
ASX - By Stock
|
315
|
147K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Dungiven
|
4.4K |
2.0M |
7 |
16/08/24 |
16/08/24 |
ASX - By Stock
|
4.4K
|
2.0M
|
7
|
|
ASX - By Stock
|
PAR |
Re:
PAR. SP
|
|
Dungiven
|
1.0K |
367K |
22 |
13/08/24 |
13/08/24 |
ASX - By Stock
|
1.0K
|
367K
|
22
|
|
ASX - By Stock
|
PAR |
Re:
PAR. SP
|
|
Dungiven
|
1.0K |
367K |
40 |
12/08/24 |
12/08/24 |
ASX - By Stock
|
1.0K
|
367K
|
40
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Dungiven
|
4.4K |
2.0M |
14 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
4.4K
|
2.0M
|
14
|
|
ASX - By Stock
|
PAR |
Re:
PARate Day 2024 - scurvy dogs o' the ASX
|
|
Dungiven
|
108 |
31K |
3 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
108
|
31K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
PARate Day 2024 - scurvy dogs o' the ASX
|
|
Dungiven
|
108 |
31K |
6 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
108
|
31K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
Dungiven
|
706 |
253K |
12 |
24/06/24 |
24/06/24 |
ASX - By Stock
|
706
|
253K
|
12
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
Dungiven
|
706 |
253K |
4 |
23/06/24 |
23/06/24 |
ASX - By Stock
|
706
|
253K
|
4
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Revised Mineral Resource Estimate - Letlhakane
|
|
Dungiven
|
6 |
3.9K |
8 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
6
|
3.9K
|
8
|
|
ASX - By Stock
|
PAR Medicine |
Re:
Why Zilosul could be a golden goose!!
|
|
Dungiven
|
117 |
53K |
5 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
117
|
53K
|
5
|
|
ASX - By Stock
|
PAR Medicine |
Re:
Why Zilosul could be a golden goose!!
|
|
Dungiven
|
117 |
53K |
1 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
117
|
53K
|
1
|
|
ASX - By Stock
|
PAR Medicine |
Re:
Why Zilosul could be a golden goose!!
|
|
Dungiven
|
117 |
53K |
5 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
117
|
53K
|
5
|
|
ASX - By Stock
|
LOT |
Re:
LOT Chart
|
|
Dungiven
|
315 |
147K |
7 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
315
|
147K
|
7
|
|
ASX - By Stock
|
PAR Medicine |
Re:
Why Zilosul could be a golden goose!!
|
|
Dungiven
|
117 |
53K |
10 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
117
|
53K
|
10
|
|
ASX - By Stock
|
PAR Medicine |
Re:
Why Zilosul could be a golden goose!!
|
|
Dungiven
|
117 |
53K |
10 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
117
|
53K
|
10
|
|
ASX - By Stock
|
PAR Medicine |
Re:
Why Zilosul could be a golden goose!!
|
|
Dungiven
|
117 |
53K |
0 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
117
|
53K
|
0
|
|
ASX - By Stock
|
PAR Medicine |
Re:
Why Zilosul could be a golden goose!!
|
|
Dungiven
|
117 |
53K |
1 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
117
|
53K
|
1
|
|
ASX - By Stock
|
PAR Medicine |
Re:
Why Zilosul could be a golden goose!!
|
|
Dungiven
|
117 |
53K |
2 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
117
|
53K
|
2
|
|
ASX - By Stock
|
PAR Medicine |
Re:
Why Zilosul could be a golden goose!!
|
|
Dungiven
|
117 |
53K |
7 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
117
|
53K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
Dungiven
|
4.2K |
3.8M |
32 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
4.2K
|
3.8M
|
32
|
|
ASX - By Stock
|
LOT |
Re:
Uranium news
|
|
Dungiven
|
97 |
47K |
3 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
97
|
47K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
Dungiven
|
706 |
253K |
8 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
706
|
253K
|
8
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
Dungiven
|
706 |
253K |
21 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
706
|
253K
|
21
|
|
ASX - By Stock
|
PAR |
Re:
2x2 Yay Or Nay From The FDA?
|
|
Dungiven
|
13 |
4.9K |
12 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
13
|
4.9K
|
12
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Type D Response Submitted and Received by the US FDA
|
|
Dungiven
|
46 |
17K |
6 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
46
|
17K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Type D Response Submitted and Received by the US FDA
|
|
Dungiven
|
46 |
17K |
26 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
46
|
17K
|
26
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Type D Response Submitted and Received by the US FDA
|
|
Dungiven
|
46 |
17K |
8 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
46
|
17K
|
8
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Type D Response Submitted and Received by the US FDA
|
|
Dungiven
|
46 |
17K |
34 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
46
|
17K
|
34
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
Dungiven
|
706 |
253K |
12 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
706
|
253K
|
12
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Dungiven
|
670 |
260K |
10 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
670
|
260K
|
10
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Appointment of Debt Advisor for Kayelekera Restart
|
|
Dungiven
|
3 |
1.3K |
4 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
3
|
1.3K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Dungiven
|
670 |
260K |
16 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
670
|
260K
|
16
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Malawian Mining Ministry Support for Kayelekera
|
|
Dungiven
|
9 |
3.5K |
1 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
9
|
3.5K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Dungiven
|
670 |
260K |
3 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
670
|
260K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Dungiven
|
670 |
260K |
10 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
670
|
260K
|
10
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Dungiven
|
670 |
260K |
19 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
670
|
260K
|
19
|
|
ASX - By Stock
|
LOT |
Re:
Ann: $30million Placement for Uranium Restart & Development
|
|
Dungiven
|
31 |
14K |
3 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
31
|
14K
|
3
|
|
ASX - By Stock
|
LOT |
Re:
Ann: $30million Placement for Uranium Restart & Development
|
|
Dungiven
|
31 |
14K |
4 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
31
|
14K
|
4
|
|
ASX - By Stock
|
LOT |
Re:
Ann: $30million Placement for Uranium Restart & Development
|
|
Dungiven
|
31 |
14K |
12 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
31
|
14K
|
12
|
|
ASX - By Stock
|
PAR |
Re:
Video: Paradigm Biopharmaceuticals (ASX:PAR) conducting Phase 3 osteoarthritis trial
|
|
Dungiven
|
31 |
10K |
4 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
31
|
10K
|
4
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Trading Halt
|
|
Dungiven
|
15 |
8.5K |
4 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
15
|
8.5K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Video: Paradigm Biopharmaceuticals (ASX:PAR) conducting Phase 3 osteoarthritis trial
|
|
Dungiven
|
31 |
10K |
32 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
31
|
10K
|
32
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Trading Halt
|
|
Dungiven
|
15 |
8.5K |
17 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
15
|
8.5K
|
17
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Trading Halt
|
|
Dungiven
|
15 |
8.5K |
1 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
15
|
8.5K
|
1
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Trading Halt
|
|
Dungiven
|
15 |
8.5K |
4 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
15
|
8.5K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
Dungiven
|
327 |
108K |
9 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
327
|
108K
|
9
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
Dungiven
|
327 |
108K |
8 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
327
|
108K
|
8
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
Dungiven
|
327 |
108K |
20 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
327
|
108K
|
20
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
Dungiven
|
327 |
108K |
31 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
327
|
108K
|
31
|
|